drugset / Trial / NCT01869634
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of systemic immune activation, and improved HIV-associated cardiovascular disease (CVD) risk.
Timeline
- Start
- 2013-06
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Darunavir | Small molecule | 800 mg | Oral |
| Comparator | Ritonavir | Other / unclassified | 100 mg | Oral |
| Comparator | Tenofovir disoproxil fumarate | Small molecule | — | Oral |
| Comparator | emtricitabine | Other / unclassified | — | Oral |